Scarica l'app Stockscreener
9.61
2.14%
-0.21
Precedente Chiudi:
$9.82
Aprire:
$9.78
Volume 24 ore:
37,647
Relative Volume:
0.71
Capitalizzazione di mercato:
$200.19M
Reddito:
-
Utile/perdita netta:
$-28.50M
Rapporto P/E:
-5.3012
EPS:
-1.8128
Flusso di cassa netto:
$-25.87M
1 W Prestazione:
-4.19%
1M Prestazione:
+6.72%
6M Prestazione:
-16.43%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.6001
$10.10
Intervallo di 1 settimana:
$9.57
$10.22
Portata 52W:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Nome
Satellos Bioscience Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare MSLE vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
9.61 | 208.73M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-06 | Iniziato | Leerink Partners | Outperform |
| 2026-03-11 | Iniziato | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Borsa (MSLE) Ultime notizie
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility - TipRanks
Satellos Bioscience (MSLE) enters $50M at-the-market share deal - Stock Titan
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside - TradingView
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.92, Implies 123% Upside - TradingView
Satellos Bioscience: Q2 Earnings Snapshot - AOL.com
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base - TipRanks
Satellos Q2 loss widens to $11.7M, EPS misses estimates - scanx.trade
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - The Manila Times
Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash - Stock Titan
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Satellos reports stable strength in four-adult Duchenne study - Stock Titan
Satellos Bioscience (MSLE) Institutional Ownership 2026 - MarketBeat
Satellos Bioscience Files For Mixed Shelf Of Up To $300 Million - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Stock Declines as Biotech Risks and Funding Concerns Pressure Sentiment - kalkine.ca
Satellos Bioscience (TSX:MSCL): Can This Toronto Biotech Actually Regrow Muscle in Duchenne Patients? - kalkine.ca
Satellos Bioscience Stock Climbs as Duchenne Therapy Data Strengthen Bullish Momentum: Can TSX:MSCL Extend Its Recovery? - kalkine.ca
Satellos Wins FDA Fast Track for SAT-3247 as Its Duchenne Programme Enters a Catalyst-Rich Second Half - kalkine.ca
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
Satellos Bioscience Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Faces Crucial Smallcap Tests - Kalkine Media
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
Satellos Bioscience Ord Shs (MSLE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Satellos Bioscience Ord Shs (MSLE) Institutional Confidence - tradingkey.com
Satellos Bioscience Inc Revenue Breakdown – LSX:A4211W - TradingView
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
What's Going On With Satellos Bioscience Inc. Stock Wednesday? - Wealth Awesome
Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
Independent Director of Satellos Bioscience Picks Up 1.9% More Stock - simplywall.st
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Spending; Stock Rises Despite EPS MissGross Profit Margin - dars.gov.et
What's Going On With Satellos Bioscience Inc. Stock Thursday? - Wealth Awesome
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: EPS Misses Estimates as Development Costs ContinueEarnings Beat Alert - dars.gov.et
What is HC Wainwright's Forecast for MSLE FY2029 Earnings? - MarketBeat
Price to book forward of Satellos Bioscience Inc – SWB:0IT - TradingView
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos Bioscience (MSLE) Extends Gains: Shares Up 3.71% as Resistance at $10.28 LoomsSafe Entry Stocks - dars.gov.et
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports
Biotech With Muscle Disease Drug Uncovers Results in Trial Data - Streetwise Reports
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data By Investing.com - Investing.com India
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data - Investing.com South Africa
Satellos reports six-month Phase II data for SAT-3247 in Duchenne muscular dystrophy - The Pharma Letter
HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock - MarketBeat
MSLE Maintained by HC Wainwright & Co. -- Price Target Raised to $18.00 - GuruFocus
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Investing News Network
Phase II DMD Trailhead data hike Satellos’ stock - bioworld.com
Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD - Moomoo
Satellos reports positive TRAILHEAD data for DMD drug - grafa.com
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Yahoo Finance
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients - TipRanks
Satellos Bioscience Inc Azioni (MSLE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):